Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| TX45 | Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF) | Phase 2 | Feb 15, 2027 | Potential moverMgmt interest |
| TX45 | Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD) | Phase 2 | Mar 31, 2029 | — |
| TX2100 | Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1a | Sep 30, 2026 | Mgmt interest |
Upcoming milestones
Company profile
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Hereditary Hemorrhagic Telangiectasia (HHT)
Data readoutPulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)
Data readout